Laboratories Thissen SA Files for Bankruptcy
Published: Nov 16, 2011
After the bankruptcy filing it is anticipated that the Court will shortly appoint a Receiver for the site who will review the potential options for its future.
The principal activity at Laboratoires Thissen SA is the commercial scale manufacturing of sterile cytotoxic products, primarily used for the treatment of cancer. The site currently manufactures products for a number of customers and employs around 300 staff. The bankruptcy filing is necessary due to a number of customers of the site significantly reducing their orders in 2011 as a result of in-sourcing production or over-stocking in other markets, leading to a 30% reduction in volumes and revenues compared with 2010 and a forecast EBITDA loss of around €5.0m in 2011. Only this year, NextPharma has injected €4.7m to Laboratoires Thissen, thereby supporting the business financially whilst the site investment and restructuring programme was being evaluated.
The restructuring required to return the site to sustainable profit, demands a major reorganisation, completion of the site’s Sterile Product Development Centre which was intended to be the catalyst for developing new products, and significant investments in new sterile manufacturing capacities and capabilities. Following a thorough strategic review of its operations, unfortunately NextPharma is unable to further support Laboratoires Thissen, without risking the stability of the wider NextPharma business.
The Board of Directors has taken note of the fact that Laboratoires Thissen was in a critical financial situation, and had no longer the support of its major lender.
Franck Latrille, Chief Executive Officer, NextPharma Technologies Holding Limited, said, “It is regrettable that this step has had to be taken which will no doubt cause concern, particularly amongst our employees. However, having undertaken a thorough strategic review of our operations, we are unable to make the financial investment required to secure the future of Laboratoires Thissen without risking the stability of the wider NextPharma business.
“The next few days will be critical in determining the options for the site and I urge full co-operation with the Receivers who are due to be appointed shortly.”